Mayville Engineering Down Over 17%, on Pace for Largest Percent Decrease Since November 2024 -- Data Talk
Dow Jones2026/11/05 18:55Mayville Engineering Company, Inc. (MEC) is currently at $13.21, down $2.80 or 17.49%
--Would be lowest close since Oct. 26, 2026, when it closed at $13.10
--On pace for largest percent decrease since Nov. 6, 2024, when it fell 19.62%
--Currently down two consecutive days; down 17.75% over this period
--Worst two day stretch since the two days ending Nov. 7, 2024, when it fell 24.53%
--Down 29.43% year-to-date; on pace for worst year on record (Based on available data back to May 9, 2019)
--Down 64.81% from its all-time closing high of $37.54 on June 29, 2026
--Down 20.85% from 52 weeks ago (Nov. 6, 2025), when it closed at $16.69
--Down 64.81% from its 52-week closing high of $37.54 on June 29, 2026
--Up 3.93% from its 52-week closing low of $12.71 on Oct. 23, 2026
--Traded as low as $13.21; lowest intraday level since Oct. 27, 2026, when it hit $13.15
--Down 17.49% at today's intraday low; largest intraday percent decrease since Aug. 6, 2025, when it fell as much as 27.63%
All data as of 1:52:56 PM ET
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
November 05, 2026 13:55 ET (18:55 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Rocket Lab’s stock falls as quarterly loss exceeds expectations
BUZZ-Take-Two shares rise after raising annual revenue and profit forecasts
Itaúsa Q3 2026 recurring net profit rises 25% to R$ 5.06 billion year-on-year
The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.
NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.
Crypto prices
More
